Pictet Asset Management Holding SA Purchases 2,928 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Pictet Asset Management Holding SA increased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 10.5% during the 4th quarter, HoldingsChannel reports. The fund owned 30,885 shares of the biotechnology company’s stock after purchasing an additional 2,928 shares during the quarter. Pictet Asset Management Holding SA’s holdings in ADMA Biologics were worth $530,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. National Bank of Canada FI bought a new stake in ADMA Biologics during the 3rd quarter worth about $35,000. GAMMA Investing LLC raised its stake in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC acquired a new position in ADMA Biologics in the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics in the fourth quarter valued at approximately $51,000. Finally, AlphaQuest LLC acquired a new stake in ADMA Biologics during the 4th quarter worth $84,000. Institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Down 2.9 %

ADMA Biologics stock opened at $17.86 on Wednesday. The firm has a market capitalization of $4.22 billion, a price-to-earnings ratio of 63.79 and a beta of 0.53. The company’s 50 day simple moving average is $17.55 and its 200 day simple moving average is $18.16. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.